Truy cp ngy 01 thng 11 nm 2024 ^ Tc gi Kaushik Kuche, Nallamothu Bhargavi (Ngy ng 04 thng 01 nm 2019)
Despite the promising results, challenges remain, including the well-known gastrointestinal side effects associated with semaglutide
In light of this potential significant safety issue, the development of Lotiglipron has been discontinued, meaning the drug did not progress to further clinical trial stages to evaluate its efficacy and safety
Its unique mechanism often leads to more significant weight loss compared to single-agonist therapies
This is a potential concern for long-term storage of MT-II in basic buffers
Bachiller S, Hidalgo I, Garcia MG, Boza-Serrano A, Paulus A, Denis Q, et al